170 Participants Needed

Coronary Dilatation Catheter for Heart Disease

Recruiting at 14 trial locations
DM
Overseen ByDebbie Morrell, MSME
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you have a known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, or anti-platelet medications, you may not be eligible to participate.

What data supports the effectiveness of the Sapphire 3 Coronary Dilatation Catheter treatment for heart disease?

Research on similar treatments, like percutaneous transluminal coronary angioplasty (PTCA), shows that it can successfully widen narrowed coronary arteries, improving blood flow and reducing symptoms in many patients. The success rate for PTCA is high, with significant improvements in heart function and reduced symptoms of angina (chest pain).12345

Is the Sapphire 3 Coronary Dilatation Catheter safe for use in humans?

The Sapphire 3 Coronary Dilatation Catheter, used in procedures like percutaneous transluminal coronary angioplasty (PTCA), has been associated with some risks such as restenosis (re-narrowing of the artery) and complications like coronary dissection and occlusion. However, advancements in technology have improved success rates and reduced complications over time, making it generally safer for use in humans.678910

How does the Sapphire 3 Coronary Dilatation Catheter treatment differ from other treatments for heart disease?

The Sapphire 3 Coronary Dilatation Catheter is unique because it is a specialized balloon catheter used in percutaneous transluminal coronary angioplasty (PTCA) to dilate narrowed coronary arteries, improving blood flow to the heart. Unlike some other treatments, it offers a non-surgical option for patients with severe coronary artery narrowings, potentially reducing the need for more invasive procedures like coronary artery bypass grafting (CABG).3581112

What is the purpose of this trial?

A prospective, open label, multi-center, single arm, observational study designed to evaluate the acute safety and device performance of the Sapphire 3 0.85, 1.0 and 1.25mm diameter coronary dilatation catheter in predilatation of Chronic Total Occlusion (CTO) lesions during percutaneous coronary intervention.One hundred seventy (170) subjects will be enrolled with a target of one hundred fifty-three (153) evaluable subjects by the angiographic core laboratory at up to 15 clinical sites with the Sapphire 3 0.85, 1.0 and 1.25mm diameter PTCA dilatation catheter to pre-dilate CTO lesions in coronary arteries during their index procedure. All subjects will be screened according to the protocol inclusion and exclusion criteria and will be followed through study completion, which is defined as 24-hours post-procedure or hospital discharge, whichever comes first.

Research Team

David Edward Kandzari, MD - Atlanta, GA

David Kandzari, MD

Principal Investigator

Piedmont Heart Institute

Eligibility Criteria

This trial is for adults with certain heart conditions like chronic total occlusion and coronary artery disease. Participants must have one or two lesions in their arteries, be over 18, give written consent, not join other studies that conflict with this one during hospitalization, and are scheduled for a stent placement.

Inclusion Criteria

Subject or a legally authorized representative must provide written informed consent prior to any study related procedures
Subject must agree not to participate in any other clinical study during hospitalization for the index procedure that would interfere with the endpoints of this study
I have a blocked artery in my heart that has been present for at least 3 months.
See 4 more

Exclusion Criteria

My heart's artery spasms without major blockage.
I have had a heart procedure within the last 30 days.
My heart condition requires multiple stents due to a blockage at a branch point.
See 14 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants undergo percutaneous coronary intervention using the Sapphire 3 Coronary Dilatation Catheter to pre-dilate CTO lesions

Peri-procedural
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after the procedure

24 hours post-procedure or until hospital discharge

Treatment Details

Interventions

  • Sapphire 3 Coronary Dilatation Catheter
Trial Overview The Sapphire 3 Coronary Dilatation Catheter is being tested to see how safe it is and how well it works when used to open up blocked arteries in the heart before placing a stent. This study will observe patients after they undergo this procedure.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Sapphire 3 Coronary Dilatation CatheterExperimental Treatment1 Intervention
Single arm with investigational Sapphire 3 Coronary Dilatation Catheters

Sapphire 3 Coronary Dilatation Catheter is already approved in United States for the following indications:

🇺🇸
Approved in United States as Sapphire 3 Coronary Dilatation Catheter for:
  • balloon pre-dilatation of a stenotic portion of a coronary artery or bypass graft stenosis (≥70% stenosis) for the purpose of improving myocardial perfusion

Find a Clinic Near You

Who Is Running the Clinical Trial?

OrbusNeich

Lead Sponsor

Trials
19
Recruited
11,800+

Avania

Industry Sponsor

Trials
59
Recruited
10,000+

Findings from Research

A 3-month cardiac rehabilitation program significantly improved cardiorespiratory function in patients who underwent either percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG), with both groups showing increased peak oxygen uptake (VO2peak).
Patients who had CABG demonstrated a greater percentage increase in VO2peak (32.8%) compared to those who had PTCA (14.6%), indicating that CABG patients had a higher training potential despite starting with lower fitness levels.
Improvement of cardiorespiratory function after percutaneous transluminal coronary angioplasty or coronary artery bypass grafting.Lan, C., Chen, SY., Hsu, CJ., et al.[2019]
Percutaneous transluminal coronary angioplasty (PTCA) has become a key treatment option for coronary disease, allowing up to 25% of patients needing myocardial revascularization to avoid more invasive bypass surgery.
The review covers various aspects of PTCA, including techniques, clinical outcomes, and recent advancements, highlighting its effectiveness and the importance of careful case selection to minimize complications.
Percutaneous transluminal coronary angioplasty.Levin, DC., Boxt, LM., Meyerovitz, MF.[2016]
In a study involving 15 patients with severe coronary artery narrowings, percutaneous transluminal coronary angioplasty (PTCA) successfully dilated narrowed arteries in 56% of cases, leading to significant symptom improvement and enhanced myocardial performance.
PTCA was particularly effective for lesions in the left-anterior descending artery, achieving a 70% success rate, and demonstrated its potential as a nonoperative method to improve blood flow to the heart.
Nonsurgical myocardial revascularization: initial experience with percutaneous transluminal coronary angioplasty.Lewis, BS., Halon, DA., Weiss, AT., et al.[2004]

References

Improvement of cardiorespiratory function after percutaneous transluminal coronary angioplasty or coronary artery bypass grafting. [2019]
Percutaneous transluminal coronary angioplasty. [2016]
Nonsurgical myocardial revascularization: initial experience with percutaneous transluminal coronary angioplasty. [2004]
[Percutaneous transluminal coronary angioplasty in ischemic heart disease]. [2010]
Clinical experience with the ACS RX Lifestream coronary dilatation catheter: a new low profile perfusion balloon catheter. [2016]
[Interventional therapy of bypass stenoses]. [2016]
Cardiovascular devices; reclassification of certain percutaneous transluminal coronary angioplasty (PTCA) catheters. Final rule. [2010]
[Percutaneous transluminal coronary angioplasty and directional coronary atherectomy: a short review of recent progress]. [2010]
Operative procedures not involving the heart after percutaneous transluminal coronary angioplasty. [2010]
Percutaneous transluminal coronary angioplasty: current status and future trends. [2019]
[Gradual coronary dilatation using double balloon catheters]. [2012]
[Percutaneous transluminal dilation by catheter of coronary - artery stenosis (author's transl)]. [2006]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security